View all Learning Zone activities
The role of measurable residual disease in acute lymphoblastic leukaemia
Watch leading experts Aaron Logan, Joseph Khoury and Nicola Gökbuget discuss the importance of measurable residual disease reporting in acute lymphoblastic lymphoma, as well as best practice techniques, potential limitations, and future directions.
Dermatitis management and chlormethine gel: new key learning points
Watch this symposium discussing contact dermatitis management in MF-CTCL. Filmed during the 4th World Congress of Cutaneous Lymphomas on February 12, 2020 in Barcelona, Spain. Watch the symposium presentation from Dr Brian Poligone Watch Now
The Role of High-Dose IL-2 in mRCC today
Watch leading experts discuss recent developments in checkpoint inhibitor therapy to treat mRCC,5,6 and the findings from a recent analysis of the PROCLAIMSM registry.
First-line Treatment Options for Renal Cell Carcinoma
Dr Ulka Vaishampayan, from Karmanos Cancer Institute, Wayne State University, MI, USA, discusses first-line treatment options for renal cell carcinoma, including the promising findings from the PROCLAIM registry, which suggest that high dose interleukin-2 is safe and effective before targeted therapy and immune checkpoint blockade.
Realising the Promise of Cell Therapy – The Automated In-house CAR T cell Manufacturing System
Chimeric antigen receptor T cells are providing us with a new option for the treatment of B cell malignancies that are non-responsive to standard therapies. Trial results and the potential of this new technology to treat a wider range of cancers are discussed in this Insight.
Molecular Re-classification of Breast Cancer – Part 2
Prof. Joyce O’Shaughnessy, of Baylor University Medical Center, TX, USA shares her insights on molecular re-classification of breast cancer, and what she believes are the most promising emerging therapeutic agents.
Molecular Re-classification of Breast Cancer – Part 1
Watch Prof. Rebecca Dent, from the National Cancer Center in Singapore discussing the re-classification of breast cancer in light of advances in understanding of tumour evolution through molecular analysis; and the need for new personalised treatment options.
Risk Stratification of Patients with Hormone-Receptor Positive Breast Cancer to Optimise Treatment Selection
Watch Prof. Peter Schmid, of the St. Bartholomew Breast Cancer Centre in the UK give his perspective on risk stratification for patients with hormone-receptor positive breast cancer; and ways in which this decision-making can be made less subjective in future.
Olaparib as a Maintenance Therapy for Ovarian Cancer and its use in BRCA-related Metastatic Breast Cancer
Recent results from trials with olaparib, a potent oral poly(ADP-ribose) polymerase inhibitor, are discussed in this Insight. Positive data and regulatory approvals are demonstrating that targeting the underlying genetic causes of a cancer can be a powerful tool for the development of new treatments with efficacy across different cancer types.
Content in this section is sponsored by the pharmaceutical industry and is developed by Touch Medical Communications (TMC) for touchONCOLOGY.
TMC’s mission is to provide HCPs with key education and communication through our unique Touch platform which combines clinical expertise with unparalleled society partnerships, long-term expert relationships and the Touch journal heritage, ultimately leading to fast implementation of positive clinical practice changes and improved patient outcomes. TMC’s "learner first" approach means that programming is delivered in multiple formats and can be accessed via multiple platforms, including mobile, allowing today’s on-the-go healthcare professionals to learn in the way that best suits them.
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!